Effect of intra-arterial nimodipine on iatrogenic vasospasms during endovascular stroke treatment - angiographic resolution and infarct growth in follow-up imaging.
Humans
Nimodipine
/ therapeutic use
Retrospective Studies
Follow-Up Studies
Treatment Outcome
Stroke
/ diagnostic imaging
Intracranial Hemorrhages
/ etiology
Thrombectomy
/ methods
Autonomic Nervous System Diseases
/ etiology
Infarction
/ etiology
Iatrogenic Disease
Endovascular Procedures
/ methods
Brain Ischemia
/ drug therapy
ASPECTS
Endovascular stroke treatment
Intracranial hemorrhage
Nimodipine
Thrombectomy
Vasospasm
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
05 Jan 2023
05 Jan 2023
Historique:
received:
11
10
2022
accepted:
27
12
2022
entrez:
5
1
2023
pubmed:
6
1
2023
medline:
10
1
2023
Statut:
epublish
Résumé
The treatment of vasospasms during endovascular stroke treatment (EST) with intra-arterial nimodipine (NM) is routinely performed. However, the efficacy of resolving iatrogenic vasospasms during the angiographic intervention and the infarct development in follow-up imaging after EST has not been studied yet. Retrospective single-center analysis of patients receiving EST for anterior circulation vessel occlusion between 01/2015 and 12/2021. The primary endpoint was ASPECTS in follow-up imaging. Secondary endpoints were the clinical outcome (combined endpoint NIHSS 24 h after EST and difference between modified Rankin Scale (mRS) before stroke and at discharge (delta mRS)) and intracranial hemorrhage (ICH) in follow-up imaging. Patients with vasospasms receiving NM (NM+) or not (NM-) were compared in univariate analysis. Vasospasms occurred in 79/1283 patients (6.2%), who consecutively received intra-arterial NM during EST. The targeted vasospasm angiographically resolved in 84% (66/79) under NM therapy. ASPECTS was lower in follow-up imaging after vasospasms and NM-treatment (NM - 7 (6-9), NM + 6 (4.5-8), p = 0.013) and the clinical outcome was worse (NIHSS 24 h after EST was higher in patients treated with NM (median, IQR; NM+: 14, 5-21 vs. NM-: 9, 3-18; p = 0.004), delta-mRS was higher in the NM + group (median, IQR; NM+: 3, 1-4 vs. NM-: 2, 1-2; p = 0.011)). Any ICH (NM+: 27/79, 34.2% vs. NM-: 356/1204, 29.6%; p = 0.386) and symptomatic ICH (NM+: 2/79, 2.5% vs. NM-: 21/1204, 1.7%; p = 0.609) was equally distributed between groups. Intra-arterial nimodipine during EST resolves iatrogenic vasospasms efficiently during EST without increasing intracranial hemorrhage rates. However, patients with vasospasms and NM treatment show higher infarct growth resulting in lower ASPECTS in follow-up imaging.
Identifiants
pubmed: 36604639
doi: 10.1186/s12883-022-03045-x
pii: 10.1186/s12883-022-03045-x
pmc: PMC9814217
doi:
Substances chimiques
Nimodipine
57WA9QZ5WH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5Informations de copyright
© 2023. The Author(s).
Références
J Neurointerv Surg. 2014 Mar;6(2):83-6
pubmed: 23390038
Clin Neuroradiol. 2021 Sep;31(3):745-752
pubmed: 32894352
Stroke. 2001 Sep;32(9):2005-11
pubmed: 11546889
Front Neurol. 2021 May 14;12:661955
pubmed: 34054705
Stroke. 2015 Oct;46(10):2981-6
pubmed: 26330447
Neurol Res Int. 2013;2013:373458
pubmed: 24228177
J Stroke Cerebrovasc Dis. 2013 Jan;22(1):22-7
pubmed: 21719308
Stroke. 2020 Jul;51(7):1961-1968
pubmed: 32568643
Neuroradiology. 2019 Apr;61(4):461-469
pubmed: 30778621
J Neuroimaging. 2009 Jan;19(1):61-4
pubmed: 18801002
Int J Stroke. 2018 Jun;13(4):348-361
pubmed: 29171362
Br J Neurosurg. 2012 Aug;26(4):517-24
pubmed: 22303863
AJNR Am J Neuroradiol. 2001 Sep;22(8):1534-42
pubmed: 11559501
Neuroradiology. 2014 Jun;56(6):477-86
pubmed: 24687568
Crit Care. 2007;11(4):220
pubmed: 17705883
AJNR Am J Neuroradiol. 2014 Mar;35(3):524-8
pubmed: 24029392
J Neurosurg. 2010 Jun;112(6):1208-15
pubmed: 19835470
J Neurointerv Surg. 2021 Oct;13(10):912-917
pubmed: 34158401
J Neurol. 2017 Mar;264(3):432-436
pubmed: 27325355
Neuroradiology. 2014 Jun;56(6):467-76
pubmed: 24668181